INTRODUCTION
Hypertrophic cardiomyopathy (HCM) is known as a relatively common genetic cardiovascular disease with an incidence of about 0.2% [1] among the overall population in America and 0.16% in China [2], presenting in all age groups. Although with diverse clinical presentations and courses, HCM generally includes obstructive and non-obstructive haemodynamic forms. As an important part of the pathophysiology of obstructive HCM, obstruction of the left ventricular outflow tract (LVOT) occurs because of multiple interrelated factors. Surgical septal myectomy has been proposed as the the therapeutic gold standard for the treatment of drug-refractory disabling symptoms in HCM caused by LVOT obstruction. This procedure can relieve haemodynamic disorders and has an acceptable surgical risk when performed on appropriate patients and in experienced centres [1, 3, 4]. In this paper, our latest experience of treating obstructive HCM by transaortic extended septal myectomy (TAESM) is reported.